Christian Peschel

发表

How the niche regulates hematopoietic stem cells.

Jonas Renström, R. Oostendorp, C. Peschel, 2010, Chemico-biological interactions.

Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma

Klemens Scheidhauer, Burkhard Schmidt, Markus Schwaiger, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Wolfgang A Weber, Karen Becker, Tibor Schuster, 2007, The Lancet. Oncology.

FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.

Markus Schwaiger, Andreas Buck, Axel Walch, 2012, Cancer research.

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Nikolas von Bubnoff, Richard A. Engh, R. Engh, 2011, PloS one.

A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma

Andreas K. Buck, Tibor Schuster, Markus Schwaiger, 2011, The Journal of Nuclear Medicine.

Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment

Josef Hoepfl, Michael R Speicher, M. Speicher, 2007, Proceedings of the National Academy of Sciences.

Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production

Gunther Hartmann, Hiroki Kato, Nicole Hannesschläger, 2010, Nature Immunology.

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL

Andreas K. Buck, Tibor Schuster, Markus Schwaiger, 2014, Oncotarget.

[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner

Andreas K. Buck, Tibor Schuster, Markus Schwaiger, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma

Christian Langer, Bernhard Kuster, Michele Pagano, 2012, Nature Cell Biology.

Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.

Thomas Decker, Christian Peschel, Ingo Ringshausen, 2006, Current drug targets.

Effect of Immunostimulatory CpG-Oligonucleotides in Chronic Lymphocytic Leukemia B Cells

C. Peschel, T. Decker, Thomas Decker, 2001 .

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

Kristina Schwamborn, Stefan Knop, Constantin Lapa, 2015, EMBO molecular medicine.

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

Falko Fend, Tibor Schuster, Markus Schwaiger, 2007, Clinical Cancer Research.

Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care

Bernhard Meyer, Stephanie E Combs, Helmut Friess, 2017, JMIR mHealth and uHealth.

Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment

Andreas K. Buck, Falko Fend, Tibor Schuster, 2008, Molecular Imaging and Biology.

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer

K. Götze, T. Decker, C. Peschel, 2012, Journal of Cancer Research and Clinical Oncology.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors

C. Peschel, J. Duyster, R. Kancha, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.